| COVID-19 Clinical Research Studies | Lifetime | 10 | IR 1 | 99.90 |
| Long-Term Effects of COVID-19 | Lifetime | 6 | IR 1 | 99.84 |
| Blood disorders and treatments | Lifetime | 4 | IR 1 | 99.78 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 18 | IR 1 | 99.84 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 30 | IR 1 | 99.83 |
| COVID-19 and healthcare impacts | Lifetime | 20 | IR 1 | 99.34 |
| Immune cells in cancer | Lifetime | 214 | IR 2 | 98.70 |
| Immune Cell Function and Interaction | Lifetime | 729 | IR 2 | 99.07 |
| Inflammasome and immune disorders | Lifetime | 140 | IR 2 | 98.38 |
| COVID-19 and Mental Health | Lifetime | 258 | IR 1 | 97.66 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 555 | IR 1 | 98.77 |
| MicroRNA in disease regulation | Lifetime | 657 | IR 8 | 97.98 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 305 | IR 1 | 98.29 |
| Cancer-related molecular mechanisms research | Lifetime | 966 | IR 9 | 97.51 |
| Cystic Fibrosis Research Advances | Lifetime | 284 | IR 1 | 97.60 |
| Extracellular vesicles in disease | Lifetime | 517 | IR 10 | 96.13 |
| COVID-19 Impact on Reproduction | Lifetime | 198 | IR 1 | 95.45 |
| Congenital Ear and Nasal Anomalies | Lifetime | 82 | IR 1 | 95.58 |
| IL-33, ST2, and ILC Pathways | Lifetime | 340 | IR 1 | 96.75 |
| COVID-19 epidemiological studies | Lifetime | 608 | IR 2 | 96.19 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 504 | IR 1 | 95.86 |
| Pediatric health and respiratory diseases | Lifetime | 683 | IR 3 | 95.95 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 495 | IR 1 | 92.29 |
| Kawasaki Disease and Coronary Complications | Lifetime | 331 | IR 2 | 93.55 |
| Parvovirus B19 Infection Studies | Lifetime | 719 | IR 1 | 93.55 |
| Urticaria and Related Conditions | Lifetime | 912 | IR 4 | 93.61 |
| SARS-CoV-2 detection and testing | Lifetime | 863 | IR 6 | 90.32 |
| Immune responses and vaccinations | Lifetime | 338 | IR 1 | 90.99 |
| Dermatological and COVID-19 studies | Lifetime | 279 | IR 3 | 88.46 |
| Whipple's Disease and Interleukins | Lifetime | 317 | IR 2 | 76.27 |
| COVID-19 Clinical Research Studies | 2021-2025 | 5 | IR 1 | 99.93 |
| Immune Cell Function and Interaction | 2021-2025 | 14 | IR 1 | 99.55 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 4 | IR 1 | 99.77 |
| Blood disorders and treatments | 2021-2025 | 2 | IR 1 | 99.65 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 48 | IR 1 | 99.69 |
| Immune cells in cancer | 2021-2025 | 26 | IR 2 | 98.93 |
| Long-Term Effects of COVID-19 | 2021-2025 | 60 | IR 1 | 99.07 |
| Parvovirus B19 Infection Studies | 2021-2025 | 4 | IR 1 | 98.19 |
| COVID-19 and healthcare impacts | 2021-2025 | 53 | IR 1 | 98.40 |
| Immunotherapy and Immune Responses | 2021-2025 | 66 | IR 2 | 98.76 |
| Cancer-related molecular mechanisms research | 2021-2025 | 104 | IR 9 | 98.93 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 55 | IR 1 | 98.42 |
| MicroRNA in disease regulation | 2021-2025 | 101 | IR 15 | 98.40 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 204 | IR 3 | 99.22 |
| CAR-T cell therapy research | 2021-2025 | 298 | IR 3 | 97.99 |
| Inflammasome and immune disorders | 2021-2025 | 90 | IR 2 | 95.86 |
| Tryptophan and brain disorders | 2021-2025 | 181 | IR 1 | 95.87 |
| Circular RNAs in diseases | 2021-2025 | 166 | IR 17 | 96.18 |
| Nerve injury and regeneration | 2021-2025 | 53 | IR 1 | 94.46 |
| Phagocytosis and Immune Regulation | 2021-2025 | 47 | IR 4 | 92.72 |
| Extracellular vesicles in disease | 2021-2025 | 388 | IR 13 | 94.34 |
| Dermatological and COVID-19 studies | 2021-2025 | 31 | IR 7 | 91.61 |
| COVID-19 and Mental Health | 2021-2025 | 866 | IR 20 | 93.61 |
| COVID-19 Impact on Reproduction | 2021-2025 | 229 | IR 2 | 92.84 |
| T-cell and B-cell Immunology | 2021-2025 | 337 | IR 1 | 91.96 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 101 | IR 1 | 92.88 |
| Autophagy in Disease and Therapy | 2021-2025 | 269 | IR 2 | 91.87 |
| Immune Response and Inflammation | 2021-2025 | 196 | IR 1 | 89.78 |
| Congenital Ear and Nasal Anomalies | 2021-2025 | 12 | IR 1 | 84.38 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 185 | IR 2 | 90.48 |
| interferon and immune responses | 2021-2025 | 339 | IR 2 | 89.10 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 226 | IR 2 | 88.22 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 103 | IR 7 | 87.27 |
| Neurogenesis and neuroplasticity mechanisms | 2021-2025 | 283 | IR 5 | 84.54 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 360 | IR 1 | 86.91 |
| NF-κB Signaling Pathways | 2021-2025 | 69 | IR 3 | 80.30 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 855 | IR 16 | 82.68 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 747 | IR 6 | 80.36 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 558 | IR 18 | 68.69 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 697 | IR 6 | 70.67 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 876 | IR 4 | 69.64 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 874 | IR 2 | 68.86 |
| Adenosine and Purinergic Signaling | 2021-2025 | 826 | IR 5 | 64.38 |
| Vitamin C and Antioxidants Research | 2021-2025 | 645 | IR 29 | 60.75 |
| Protein Tyrosine Phosphatases | 2021-2025 | 909 | IR 4 | 36.52 |
